Mark Zuckerberg and his wife Priscilla Chan acquired Meta through a charity foundation they set-up. They aim to spend up to $3 billion or 99 percent of their personal fortune to fund the finding of a cure for all diseases.
Meta, an AI research tool can scan through millions of medical papers published worldwide. According to Molyneux, there are about 4,000 papers regarding biomedicine that are being published every single day. A normal person - or even a group of researchers will be able to scan over all of them - but Meta is designed to collect and connect different papers for reference in just a matter of seconds.
Meta AI search tool can also rank and prioritise papers based on their relevance to each other, thus giving enormous amounts of resources and references for advanced medical breakthroughs and sciences. It simply works like Google, but Meta is designed to have a human-like eye for details. Currently, the search tool is being used by 1,200 institutes worldwide, as reported by Wired.
So the Zuckerberg-Chan project makes Meta as "single, powerful tool that is available to everyone." For now, Meta AI search tool will be available for people who needs them most - research teams around the world who focus on medical advances. Meta will be offered for free to all researchers, according to Cori Bargmann, Chan Zuckerberf Initiative president of science.
The Meta AI search tool will open possibilities for scientists to get updated with the latest in real-time. This will also encourage collaborations of researchers from different parts of the world. Since several diseases could have a link with each other, finding a way around these things will make it possible to find solutions faster than ever before.
Aside from the acquisition of Meta AI search tool, Zuckerberg proves to be serious about finding solutions as the Chan Zuckerberg Biohub chose 47 new investigators to receive $1.5 million each for five years in order do biomedical research, Berkeley News reports.
© 2023 Lawyer Herald All rights reserved. Do not reproduce without permission.
Get the Most Popular Lawyerherald Stories in a Weekly Newsletter
Join the Discussion
Related Articles
